RJA
FLGT icon

Raymond James & Associates’s Fulgent Genetics FLGT Stock Holding History

Raymond James & Associates’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,046
Closed -$275K – 4014
2022
Q2 		$275K Sell
5,046
-9,898
-66% -$544K ﹤0.01% 3287
2022
Q1 		$933K Buy
14,944
+4,486
+43% +$295K ﹤0.01% 2647
2021
Q4 		$1.05M Buy
10,458
+3,113
+42% +$274K ﹤0.01% 2587
2021
Q3 		$661K Buy
7,345
+201
+3% +$18.3K ﹤0.01% 2861
2021
Q2 		$659K Sell
7,144
-9,097
-56% -$726K ﹤0.01% 2880
2021
Q1 		$1.57M Sell
16,241
-4,208
-21% -$434K ﹤0.01% 2183
2020
Q4 		$1.06M Buy
20,449
+5,199
+34% +$217K ﹤0.01% 2303
2020
Q3 		$611K Sell
15,250
-12,170
-44% -$381K ﹤0.01% 2487
2020
Q2 		$439K Buy
27,420
+14,585
+114% +$223K ﹤0.01% 2676
2020
Q1 		$138K Sell
12,835
-2,070
-14% -$28.8K ﹤0.01% 3144
2019
Q4 		$192K Buy
+14,905
New +$177K ﹤0.01% 3360

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's FLGT Position: Q3 2022 in Review

Raymond James & Associates sold out of Fulgent Genetics (FLGT) in Q3 2022, closing a stake of 5,046 shares — an estimated $275K sold.

Raymond James & Associates first reported a position in FLGT in Q4 2019 and held it in 11 quarters. The position peaked at $1.57M in Q1 2021. 235 funds tracked by Wall St. Rank hold FLGT as of Q3 2022.

  • Raymond James & Associates reported no remaining Fulgent Genetics position as of Q3 2022 after selling out during the quarter.
  • Raymond James & Associates sold 5,046 Fulgent Genetics shares in Q3 2022, an estimated $275K.
  • Raymond James & Associates first reported a position in Fulgent Genetics in Q4 2019 and held it in 11 quarters.
  • Raymond James & Associates's Fulgent Genetics position peaked at $1.57M in Q1 2021.
  • 235 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.